GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Beta

Oculis Holding AG (Oculis Holding AG) Beta : N/A (As of May. 27, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-27), Oculis Holding AG's Beta is Not available.


Oculis Holding AG Beta Historical Data

The historical data trend for Oculis Holding AG's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Beta Chart

Oculis Holding AG Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beta
- - - -

Oculis Holding AG Quarterly Data
Dec20 Jun21 Sep21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oculis Holding AG's Beta

For the Biotechnology subindustry, Oculis Holding AG's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oculis Holding AG's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Beta distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Beta falls into.



Oculis Holding AG Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Oculis Holding AG  (NAS:OCS) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Oculis Holding AG Beta Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Oculis Holding AG (Oculis Holding AG) Business Description

Traded in Other Exchanges
Address
Bahnhofstrasse 7, Zug, CHE, 6300
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.